Perioperative coagulation management in the intensive care unit

Current Opinion in Anaesthesiology

Volumn 26, Issue 1, 2013, Pages 65-70

  Levy, Jerrold H ^a   Faraoni, David ^b   Sniecinski, Roman M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

Author keywords

Bleeding management; Coagulation monitoring; Coagulopathy; Intensive care; New oral anticoagulants

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; DESMOPRESSIN; FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; PLACEBO; PRASUGREL; PROTAMINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TRANEXAMIC ACID; WARFARIN;

ANAPHYLAXIS; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERIAL THROMBOEMBOLISM; BLEEDING; BLOOD CLOTTING DISORDER; CRITICALLY ILL PATIENT; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HEART SURGERY; HEMODIALYSIS; HEMOPHILIA; HEMOSTASIS; HUMAN; HYPOFIBRINOGENEMIA; HYPOTENSION; INTENSIVE CARE UNIT; LABORATORY TEST; LUNG FUNCTION TEST; LUNG VASOCONSTRICTION; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOSIS; TRANSFUSION; VENOUS THROMBOEMBOLISM; VISCOELASTICITY;

BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD TRANSFUSION; HEMOSTATICS; HUMANS; INTENSIVE CARE UNITS; PERIOPERATIVE CARE; RENAL DIALYSIS;

EID: 84872203944     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32835b82df     Document Type: Review

References (50)

1. Sniecinski RM, Levy JH. Bleeding and management of coagulopathy. J Thorac Cardiovasc Surg 2011; 142:662-667.
2. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2301-2311. (Pubitemid 46849160)
3. Sniecinski RM, Hursting MJ, Paidas MJ, et al. Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia. Anesth Analg 2010; 112:46-58.
4. Steiner ME, Despotis GJ. Transfusion algorithms and how they apply to blood conservation: The high-risk cardiac surgical patient. Hematol Oncol Clin North Am 2007; 21:177-L84.
5. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastographyguided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88:312-319. (Pubitemid 29070189)
6. Toulon P, Ozier Y, Ankri A, et al. Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study. Thromb Haemost 2009; 101:394-401.
7. Ganter MT, Hofer CK. Coagulation monitoring: Current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106:1366-L375.
8. Weber CF, Gorlinger K, Meininger D, et al. Point-of-care testing: A prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117:531-547.
9. Carroll RC, Chavez JJ, Snider CC, et al. Correlation of perioperative platelet function and coagulation tests with bleeding after cardiopulmonary bypass surgery. J Lab Clin Med 2006; 147:197-204.
10. Holcomb JB. Optimal use of blood products in severely injured trauma patients. Hematology Am Soc Hematol Educ Program 2010; 2010:465-469.
11. Greer SE, Rhynhart KK, Gupta R, et al. New developments in massive transfusion in trauma. Curr Opin Anaesthesiol 2010; 23:246-250.
12. Dente CJ, Shaz BH, Nicholas JM, et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma 2009; 66:1616-L624.
13. Schochl H, Maegele M, Solomon C, et al. Early and individualized goaldirected therapy for trauma-induced coagulopathy. Scand J Trauma Resusc Emerg Med 2012; 20:15.
14. Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 2001; 72:S1814-S1820. (Pubitemid 33049833)
15. Theusinger OM, Wanner GA, Emmert MY, et al. Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma. Anesth Analg 2011; 113: 1003-L012.
16. Levy JH, Tanaka KA, Steiner ME. Evaluation and management of bleeding during cardiac surgery. Curr Hematol Rep 2005; 4:368-372.
17. Levy JH. Antifibrinolytic therapy: New data and new concepts. Lancet 2010; 376:3-4.
18. Weber CF, Gorlinger K, Byhahn C, et al. Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy. Eur J Anaesthesiol 2011; 28:57-62.
19. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet 2010; 376:23-32.
20. Sniecinski RM, Chen EP, Makadia SS, et al. Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest. J Cardiothorac Vasc Anesth 2010; 24:959-963.
21. Martin K, Wiesner G, Breuer T, et al. The risks of aprotinin and tranexamic acid in cardiac surgery: A one-year follow-up of 1188 consecutive patients. Anesth Analg 2008; 107:1783-L790.
22. Sharma V, Fan J, Jerath A, et al. Pharmacokinetics of tranexamic acid in patients undergoing cardiac surgery with use of cardiopulmonary bypass. Anaesthesia 2012; 67:1242-L250.
23. Dowd NP, Karski JM, Cheng DC, et al. Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 2002; 97:390-399. (Pubitemid 34847752)
24. Naoulou B, Tsai MC. Efficacy of tranexamic acid in the treatment of idiopathic and nonfunctional heavy menstrual bleeding: A systematic review. Acta Obstet Gynecol Scand 2012; 91:529-537.
25. Levy JH, Adkinson NF Jr. Anaphylaxis during cardiac surgery: Implications for clinicians. Anesth Analg 2008; 106:392-403. (Pubitemid 351156659)
26. Kuitunen AH, Salmenpera MT, Heinonen J, et al. Heparin rebound: A comparative study of protamine chloride and protamine sulfate in patients undergoing coronary artery bypass surgery. J Cardiothorac Vasc Anesth 1991; 5:221-226.
27. Gertler R, Wiesner G, Tassani-Prell P, et al. Are the point-of-care diagnostics MULTIPLATE and ROTEM valid in the setting of high concentrations of heparin and its reversal with protamine? J Cardiothorac Vasc Anesth 2011; 25:981-986.
28. Levy JH, Schwieger IM, Zaidan JR, et al. Evaluation of patients at risk for protamine reactions. J Thorac Cardiovasc Surg 1989; 98:200-204. (Pubitemid 19198523)
29. Levy JH, Zaidan JR, Faraj B. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-Dependent diabetes. Anesth Analg 1986; 65:739-742. (Pubitemid 16085789)
30. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997; 90:2515-2521. (Pubitemid 27413458)
31. Tiede A, Rand JH, Budde U, et al. How I treat the acquired von Willebrand syndrome? Blood 2011; 117:6777-6785.
32. Mannucci PM, Carlsson S, Harris AS. Desmopressin, surgery and thrombosis. Thromb Haemost 1994; 71:154-L55.
33. Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93:1101-L107.
34. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007; 5:266-273. (Pubitemid 46139450)
35. Rourke C, Curry N, Khan S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012; 10:1342-L351.
36. Baudo F, Collins P, Huth-Kuhne A, et al. Management of bleeding in acquired hemophilia A: Results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120:39-46.
37. Romagnoli S, Bevilacqua S, Gelsomino S, et al. Small-Dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 2006; 102:1320-L326.
38. Goodnough LT, Lublin DM, Zhang L, et al. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004; 44:1325-L331.
39. Karkouti K, Levy JH. Recombinant activated factor VII: The controversial conundrum regarding its off-label use. Anesth Analg 2011; 113:711-712.
40. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-298. (Pubitemid 43112957)
41. Levi M, Levy JH, Andersen HF, et al. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791-L800.
42. Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: A randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009; 120:21-27.
43. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008; 109:918-926.
44. Guest JF, Watson HG, Limaye S. Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United kingdom. Clin Ther 2010; 32:2478-2493.
45. Garcia D. Rethinking warfarin reversal. Blood 2011; 116:675-676.
46. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116-L127.
47. Warkentin TE, Margetts P, Connolly SJ, et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119:2172-2174.
48. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 (Suppl. 1):S141-S145.
49. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebocontrolled, crossover study in healthy subjects. Circulation 2011; 124:1573-L579.
50. Marlu R, Hodaj E, Paris A, et al. Effect of nonspecific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108:217-224.